Alector Q3 net loss $44.5M ($0.53/share); cash runway through 2025

Alector, Inc.

2023-Q3 EPS reported -$1.07 revenue$81,872,000

Collaboration revenue $9.1M, down from $14.9M YoY; net loss $44.5M vs $46.1M in Q3 2022.
Cash, equivalents & investments $588.9M; management expects sufficient runway through 2025.
Completed enrollment in pivotal INFRONT-3 Phase 3 trial of latozinemab for FTD-GRN with 103 symptomatic participants.
Completed enrollment in INVOKE-2 Phase 2 trial of AL002 for early Alzheimer's; data readout expected Q4 2024.
Reaffirmed FY 2023 guidance: collaboration revenue $90-100M, R&D $210-220M, G&A $60-65M.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.85

Alector, Inc. reported financial results for the quarter ended September 30, 2023.

Period: the quarter ended September 30, 2023
Result: reported results

Exact text from the filing

On November 7, 2023, Alector, Inc. (the “Company”) announced its financial results for the quarter ended September 30, 2023.

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

Alector, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-060244

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.